CorVel (NASDAQ:CRVL) Director R Judd Jessup Sells 1,262 Shares

Key Points

• Director R. Judd Jessup sold 1,262 CorVel shares at an average price of $70.64, generating $89,147.68. Following the sale, he retained 115,821 shares valued at approximately $8.18 million.
• CorVel shares traded at $69.66, with a market capitalization of $3.55 billion. The company recently reported quarterly revenue of $259.93 million and earnings of $0.63 per share.
• Analyst sentiment remains neutral, with CorVel carrying a consensus “Hold” rating, although Wall Street Zen upgraded the stock to “Buy.” Institutional investors own 51.36% of the company.

CorVel Corp. (NASDAQ:CRVL - Get Free Report) Director R Judd Jessup sold 1,262 shares of CorVel stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $70.64, for a total transaction of $89,147.68. Following the sale, the director directly owned 115,821 shares of the company's stock, valued at $8,181,595.44. The trade was a 1.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

R Judd Jessup also recently made the following trade(s):

• On Wednesday, August 26th, R Judd Jessup sold 1,562 shares of CorVel stock. The shares were sold at an average price of $70.71, for a total transaction of $110,449.02.

CorVel Price Performance

CorVel stock traded up $0.23 during trading hours on Friday, hitting $69.66. The company had a trading volume of 42,589 shares, compared to its average volume of 218,616. The firm has a 50-day moving average of $63.19 and a 200 day moving average of $58.14. The firm has a market cap of $3.55 billion, a PE ratio of 30.96 and a beta of 0.98. CorVel Corp. has a one year low of $44.83 and a one year high of $93.45.

CorVel (NASDAQ:CRVL - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The business services provider reported $0.63 earnings per share (EPS) for the quarter. CorVel had a return on equity of 29.92% and a net margin of 11.72%.The company had revenue of $259.93 million during the quarter.

Analyst Upgrades and Downgrades

CRVL has been the topic of a number of research reports. Wall Street Zen raised CorVel from a "hold" rating to a "buy" rating in a report on Saturday, May 30th. Weiss Ratings raised shares of CorVel from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, July 16th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, CorVel has a consensus rating of "Hold".

Institutional Investors Weigh In On CorVel

A number of hedge funds and other institutional investors have recently made changes to their positions in CRVL. Northwestern Mutual Wealth Management Co. bought a new stake in shares of CorVel in the third quarter valued at approximately $31,000. Los Angeles Capital Management LLC acquired a new position in CorVel in the 4th quarter valued at $33,000. Rockefeller Capital Management L.P. raised its holdings in CorVel by 66.9% in the 4th quarter. Rockefeller Capital Management L.P. now owns 574 shares of the business services provider's stock valued at $39,000 after acquiring an additional 230 shares in the last quarter. Quarry LP lifted its position in shares of CorVel by 218.6% during the 3rd quarter. Quarry LP now owns 513 shares of the business services provider's stock valued at $40,000 after acquiring an additional 352 shares during the period. Finally, Torren Management LLC bought a new stake in shares of CorVel during the 4th quarter valued at $46,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About CorVel

CorVel Corporation NASDAQ: CRVL is a technology-driven provider of workers' compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel's integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company's product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source